Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells): The gateway to improved responses

Rebecca R. Laborde, Yi Lin, Michael Gustafson, Peggy A. Bulur, Allan B Dietz

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Dendritic cells are an important target in cancer immunotherapy based on their critical role in antigen presentation and response to tumor development. The capacity of dendritic cells to stimulate anti-tumor immunity has led investigators to use these cells to mediate anti-tumor responses in a number of clinical trials. However, these trials have had mixed results. The typical method for generation of ex vivo dendritic cells starts with the purification of CD14+ cells. Our studies identified a deficiency in the ability to generate mature dendritic cell using CD14+ cells from cancer patients that corresponded with an increased population of monocytes with altered surface marker expression (CD14+HLA-DRlo/neg). Further studies identified systemic immune suppression and increased concentrations of CD14+HLA-DRlo/neg monocytes capable of inhibiting T-cell proliferation and DC maturation. Together, these findings strongly suggest that protocols aimed at immune stimulation via monocytes/dendritic cells, if optimized on normal monocytes or in systems without these suppressive monocytes, are unlikely to engender effective DC maturation in vitro or efficiently trigger DC maturation in vivo. This highlights the importance of developing optimal protocols for stimulating DCs in the context of significantly altered monocyte phenotypes often seen in cancer patients.

Original languageEnglish (US)
Article numberArticle 147
JournalFrontiers in Immunology
Volume5
Issue numberAPR
DOIs
StatePublished - 2014

Fingerprint

Cancer Vaccines
Monocytes
Dendritic Cells
Neoplasms
Antigen Presentation
Immunotherapy
Immunity
Research Personnel
Cell Proliferation
Clinical Trials
T-Lymphocytes
Phenotype
Population

Keywords

  • Dendritic cells
  • Immunotherapy
  • MDSC
  • Monocytes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells) : The gateway to improved responses. / Laborde, Rebecca R.; Lin, Yi; Gustafson, Michael; Bulur, Peggy A.; Dietz, Allan B.

In: Frontiers in Immunology, Vol. 5, No. APR, Article 147, 2014.

Research output: Contribution to journalArticle

@article{accd21b01c8746a6bec90b5815608770,
title = "Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells): The gateway to improved responses",
abstract = "Dendritic cells are an important target in cancer immunotherapy based on their critical role in antigen presentation and response to tumor development. The capacity of dendritic cells to stimulate anti-tumor immunity has led investigators to use these cells to mediate anti-tumor responses in a number of clinical trials. However, these trials have had mixed results. The typical method for generation of ex vivo dendritic cells starts with the purification of CD14+ cells. Our studies identified a deficiency in the ability to generate mature dendritic cell using CD14+ cells from cancer patients that corresponded with an increased population of monocytes with altered surface marker expression (CD14+HLA-DRlo/neg). Further studies identified systemic immune suppression and increased concentrations of CD14+HLA-DRlo/neg monocytes capable of inhibiting T-cell proliferation and DC maturation. Together, these findings strongly suggest that protocols aimed at immune stimulation via monocytes/dendritic cells, if optimized on normal monocytes or in systems without these suppressive monocytes, are unlikely to engender effective DC maturation in vitro or efficiently trigger DC maturation in vivo. This highlights the importance of developing optimal protocols for stimulating DCs in the context of significantly altered monocyte phenotypes often seen in cancer patients.",
keywords = "Dendritic cells, Immunotherapy, MDSC, Monocytes",
author = "Laborde, {Rebecca R.} and Yi Lin and Michael Gustafson and Bulur, {Peggy A.} and Dietz, {Allan B}",
year = "2014",
doi = "10.3389/fimmu.2014.00147",
language = "English (US)",
volume = "5",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells)

T2 - The gateway to improved responses

AU - Laborde, Rebecca R.

AU - Lin, Yi

AU - Gustafson, Michael

AU - Bulur, Peggy A.

AU - Dietz, Allan B

PY - 2014

Y1 - 2014

N2 - Dendritic cells are an important target in cancer immunotherapy based on their critical role in antigen presentation and response to tumor development. The capacity of dendritic cells to stimulate anti-tumor immunity has led investigators to use these cells to mediate anti-tumor responses in a number of clinical trials. However, these trials have had mixed results. The typical method for generation of ex vivo dendritic cells starts with the purification of CD14+ cells. Our studies identified a deficiency in the ability to generate mature dendritic cell using CD14+ cells from cancer patients that corresponded with an increased population of monocytes with altered surface marker expression (CD14+HLA-DRlo/neg). Further studies identified systemic immune suppression and increased concentrations of CD14+HLA-DRlo/neg monocytes capable of inhibiting T-cell proliferation and DC maturation. Together, these findings strongly suggest that protocols aimed at immune stimulation via monocytes/dendritic cells, if optimized on normal monocytes or in systems without these suppressive monocytes, are unlikely to engender effective DC maturation in vitro or efficiently trigger DC maturation in vivo. This highlights the importance of developing optimal protocols for stimulating DCs in the context of significantly altered monocyte phenotypes often seen in cancer patients.

AB - Dendritic cells are an important target in cancer immunotherapy based on their critical role in antigen presentation and response to tumor development. The capacity of dendritic cells to stimulate anti-tumor immunity has led investigators to use these cells to mediate anti-tumor responses in a number of clinical trials. However, these trials have had mixed results. The typical method for generation of ex vivo dendritic cells starts with the purification of CD14+ cells. Our studies identified a deficiency in the ability to generate mature dendritic cell using CD14+ cells from cancer patients that corresponded with an increased population of monocytes with altered surface marker expression (CD14+HLA-DRlo/neg). Further studies identified systemic immune suppression and increased concentrations of CD14+HLA-DRlo/neg monocytes capable of inhibiting T-cell proliferation and DC maturation. Together, these findings strongly suggest that protocols aimed at immune stimulation via monocytes/dendritic cells, if optimized on normal monocytes or in systems without these suppressive monocytes, are unlikely to engender effective DC maturation in vitro or efficiently trigger DC maturation in vivo. This highlights the importance of developing optimal protocols for stimulating DCs in the context of significantly altered monocyte phenotypes often seen in cancer patients.

KW - Dendritic cells

KW - Immunotherapy

KW - MDSC

KW - Monocytes

UR - http://www.scopus.com/inward/record.url?scp=84900839768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900839768&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2014.00147

DO - 10.3389/fimmu.2014.00147

M3 - Article

AN - SCOPUS:84900839768

VL - 5

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - Article 147

ER -